Dexcom is maintaining its prior FY26 outlook in view of the current geopolitical realities such as higher oil prices due to Iran’s closure of the Strait of Hormuz in response to the US-Israel’s war ...

MintNeuro has signed a partnership with Motif Neurotech to advance the development of miniature BCI therapy for mental health conditions.

The funds will advance Axoft’s existing clinical trial programmes and progress US regulatory activities for its implantable brain-computer interface.

Neuromodulation is an adjunct to medication for Parkinson’s symptom management, with growing interest in whether it could one day contribute to disease-modifying therapies.

Should the transaction complete, J&J will inherit Atraverse’s radiofrequency system for simplifying access to the heart’s left atrium.

Tandem has received FDA approval for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type 1 diabetes mellitus.

GE HealthCare has cut its 2026 growth outlook by 3.3% at the top end, citing increasing freight costs for oil and other materials.

Swiss biotech AC Immune discusses its PET tracer's potential in realising precision medicine approaches to neurodegenerative diseases.

Nervonik has secured $52.5m in Series B financing aimed at advancing its peripheral nerve stimulation (PNS) system.

The MUSC and Revival Healthcare Capital have entered a partnership aimed at advancing the clinical development of medical technologies.

According to GlobalData analyst Dr Andrew S Thompson, the deal signals Thermo Fisher’s move away from the IVD space.

BrioHealth Solutions has secured conditional FDA approval to begin a clinical trial of its BrioVAD system in children diagnosed with advanced heart failure.